|
C5ORF51 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.36139999998386E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.43390000002009E-07 |
| Normal-vs-Stage2 |
4.579400E-04 |
| Normal-vs-Stage3 |
2.08110000010642E-07 |
| Normal-vs-Stage4 |
1.64000000246745E-08 |
| Stage1-vs-Stage2 |
4.833600E-01 |
| Stage1-vs-Stage3 |
3.005000E-01 |
| Stage1-vs-Stage4 |
5.733500E-02 |
| Stage2-vs-Stage3 |
2.006400E-01 |
| Stage2-vs-Stage4 |
4.577600E-02 |
| Stage3-vs-Stage4 |
3.151000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.39399999987688E-07 |
| Normal-vs-AfricanAmerican |
1.301700E-03 |
| Normal-vs-Asian |
2.02559999995522E-06 |
| Caucasian-vs-AfricanAmerican |
7.051800E-01 |
| Caucasian-vs-Asian |
9.960400E-01 |
| AfricanAmerican-vs-Asian |
7.316200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.04369999998077E-06 |
| Normal-vs-Female |
2.50439999960328E-07 |
| Male-vs-Female |
8.822200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67549999996464E-06 |
| Normal-vs-Age(41-60Yrs) |
2.97779999991477E-07 |
| Normal-vs-Age(61-80Yrs) |
7.42850000401418E-08 |
| Normal-vs-Age(81-100Yrs) |
6.144400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.072400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.877810E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.628200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.512200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.081000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.911000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.257900E-02 |
| Classical-VS-Follicular |
4.498200E-01 |
| Classical-VS-Other |
8.082200E-01 |
| Classical-VS-Normal |
4.45620000000257E-06 |
| Tall-VS-Follicular |
1.327380E-01 |
| Tall-VS-Other |
5.878600E-01 |
| Tall-VS-Normal |
1.03069999979333E-07 |
| Follicular-VS-Other |
9.905000E-01 |
| Follicular-VS-Normal |
1.25169999998231E-06 |
| Other-VS-Normal |
5.047900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63559998878071E-09 |
| Normal-vs-N1 |
2.00890000001674E-06 |
| N0-vs-N1 |
7.557400E-01 |
|
|
